Skip to main content

IP and Health Care Economics

Image result for watson generic drug manufacturer

A federal appeals court recently ruled that a patent on a successful birth control product is invalid  because the patent owner made an offer to sell the invention more than one year before it applied for said patent.  This sounds like a straightforward application of what patent lawyers call the "on sale bar." MERCK & Cie v. WATSON LABS, 125 F.Supp 3d 503 (D. Del. 2015).

Merck is appealing this to the SCOTUS. It sought a "stay of mandate," that is, it tried to get Chief Justice Roberts to rule that the decision would not take effect until the high court heard and decided the matter. But they failed to get the stay, so Watson, the generic drug manufacturer, gets to sell the drug at issue in the US pending further developments.

Here's a relevant brief from Watson's lawyers.

On July 27, Roberts denied that application for stay in a brief order, providing no rationale.

Merck's argument is that what it did more than one year prior to the application was not
the sort of public offer of sale that is supposed to trigger the one-year clock on a filing, and that the Federal Circuit Court has now overturned decades of precedents by treating private negotiations as a public sale.

Here's a more complete discussion:

I have no profound point to draw from all this. But the law of IP and the economics of health care are both subjects of abiding fascination for me, so their intersection is likewise.


  1. What is the rationale for the on-sale bar? (Wikipedia, which uses the hyphen, doesn't say in its "On-sale bar" entry. It discusses what constitutes a sale and when the one-year period starts.)

  2. The law incorporates an intuitive sense that before an inventor starts to sell something at all, THAT is the time to make the decision -- "shall I be putting this into the public domain, or will I seek to keep proprietary control of it?" Acting as if something is available to the public, but then, after a year, seeking to assert proprietary rights, seems capricious and likely to make life unnecessarily complicated for other parties developing related technologies. Predictability, certainty, repose, all the words of that order may be applied here.


Post a Comment

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.

We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…